Protective effect of *Palmijihwanghwan* in a mouse model of cigarette smoke and lipopolysaccharide-induced chronic obstructive pulmonary disease

Eun Bok Baek¹, Jin-kyung Rho¹, Eunhye Jung¹, Chang-Seob Seo², Jin-Hee Kim² and Hyo-Jung Kwun¹*

Abstract

**Background:** *Palmijihwanghwan* (PJH) is a traditional medicine and eight constituents derived from PJH possess anti-inflammatory activities. However, the scientific evidence for its potential as a therapeutic agent for inflammatory lung disease has not yet been studied. In this study, we examined the protective effect of PJH in a mouse model of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke (CS) with lipopolysaccharide (LPS).

**Methods:** Mice received CS exposure for 8 weeks and intranasal instillation of LPS on weeks 1, 3, 5 and 7. PJH (100 and 200 mg/kg) was administrated daily 1 h before CS treatment for the last 4 weeks.

**Results:** Compared with CS plus LPS-exposed mice, mice in the PJH-treated group showed significantly decreased inflammatory cells count and reduced inflammatory cytokines including interleukin-1 beta (IL-1β), IL-6 and tumor necrosis factor alpha (TNF-α) levels in broncho-alveolar lavage fluid (BALF) and lung tissue. PJH also suppressed the phosphorylation of nuclear factor kappa B (NF-κB) and extracellular signal-regulated kinase1/2 (ERK1/2) caused by CS plus LPS exposure. Furthermore, CS plus LPS induced increases in matrix metallopeptidase (MMP)-7, MMP-9, and transforming growth factor-β (TGF-β) expression and collagen deposition that were inhibited in PJH-treated mice.

**Conclusions:** This study demonstrates that PJH prevents respiratory inflammation and airway remodeling caused by CS with LPS exposure suggesting potential therapy for the treatment of COPD.

**Keywords:** Airway remodeling, Chronic obstructive pulmonary disease, *Palmijihwanghwan*, Cigarette smoke, Inflammation

Background

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease associated with persistent respiratory symptoms such as dyspnea, sputum over-production, and cough [1]. COPD encompasses chronic obstructive bronchiolitis with subsequent fibrosis and closure of airways, and emphysema with expansion of airspaces [2]. COPD pathophysiology is characterized by persistent airway inflammation reflecting activated inflammatory cells (e.g., neutrophils, eosinophils, macrophages and lymphocytes) and pulmonary emphysema [3]. A history of exposure to inhaled toxic particles, smoke, such as cigarette smoke (CS), or gases is associated with the diagnosis of COPD [4]. Harmful particles of inhaled CS give rise to the airway inflammation and pulmonary damage that predominates in COPD patients.
CS is metabolized to numerous toxic chemical substances that generate reactive oxygen species (ROS), which play a major role in the pathogenesis of COPD [5]. In fact, markers of oxidative stress, including nitrogen oxides and lipid peroxides, are elevated in the respiratory tract, blood, and lung tissues of COPD patients [6].

Current pharmacological therapy of COPD involves long-acting anti-muscarinic agents (LAMAs), long-acting β2 agonists (LABAs), inhaled corticosteroids, inhibitors of phosphodiesterase-4 (PDE4), such as rolflumilast, and their combination therapies [7, 8]. Adverse drug reactions associated with several classes of drugs, including corticosteroids and PDE4 inhibitors, especially theophylline, have been reported, highlighting the need for alternative therapies, in particular, herbal products [9]. Herbal therapies for COPD are intended to mitigate symptoms, prevent recurrence, reduce the risk of comorbidities and improve the quality of life.

The levels of a number of specific inflammatory mediators, including several cytokines and chemokines that promote inflammatory process and influx immune cells into the lungs, are increased in lung tissues of COPD patients. These pro-inflammatory mediators are regulated by activation of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), particularly p38 MAPK and extracellular signal-regulated kinase (ERK)-1 and −2 [1]. Increased ROS released from inflammatory cells, such as leukocytes and macrophages, are involved in the inflammatory progress in the lungs of COPD patients. They also generate chemokines the guide the inflow of excessive inflammatory cells, such as neutrophils, monocytes and lymphocytes, into the lung [10].

The herbal formula Palmijihwanghwan (PJH) is a traditional medicine in the Asian continent and also called Hachimi-Jio-Gan in Japan and Ba-Wei-Di-Huang-Wan in China [11]. It has been clinically used to treat many symptoms, such as diabetes, hypertension, back pain, edema, nephritis and dementia [12–15]. PJH is composed of eight herbal extracts including Dioscorea batatas, Paeonia suffruticosa, Rehmannia glutinosa, Cornus officinalis, Aconitum carmichaelii, Cinnamomum cassia, Alisma orientale, and Poria cocos. Among these herbal mixtures, for example, Dioscorea batatas shows anti-inflammatory effects and regulates energy metabolism, and 2, 7-dihydroxy-4, 6-dimethoxy phenanthrene isolated from Dioscorea batatas decreased the expression of proinflammatory cytokines and posed potential as a therapeutic agent for multiple inflammatory diseases, such as COPD [16, 17]. Paeonia suffruticosa improved lipopolysaccharide-induced acute lung injury in rats through anti-inflammation [18]. Rehmannia glutinosa is a major ingredient of PM014, which prevented inflammatory processes in mouse COPD models [19]. Corni fructus, which is a fruit of Cornus officinalis, showed therapeutic effects in ovalbumin-induced asthma animal model [20]. In addition, Cornus officinalis shows anti-inflammatory and analgesic effects [21]. Aconitum carmichaelii protected against sepsis-induced acute lung injury and has been used as an anti-inflammatory and analgesic therapies in Asian continent [22–24]. Cinnamomum cassia Blume is a popular traditional Chinese herbal medicine that has been used to manage respiratory tract disease and anti-inflammatory effect of Cinnamomum cassia was reported [25, 26]. Alisma orientale has been prescribed as a remedy for treating the diseases associated with body fluid dysfunction such as edema and inflammatory lung diseases [27]. Poria cocos exerted anticancer properties, especially against lung cancer [28].

Despite multiple previous reports on PJH constituents, none has investigated its protective effect in an animal model of chronic COPD. Here, we assessed the therapeutic effects of PJH in a mouse model of COPD induced by CS combined with LPS (CS/LPS) and investigated potential mechanisms. In the present work, PJH showed protective effects against inflammatory disease progression in a CS/LPS-induced COPD mouse model.

Materials and methods
Preparation of PJH
PJH granules were obtained from Korea Syntex Pharmaceutical (Jeonbuk, South Korea) and stored in the Herbal Medicine Research Division of the Korea Institute of Oriental Medicine (Daejeon, South Korea). For UPLC-DAD-MS/MS analyses, PJH was dissolved in methanol to a concentration of 50 mg/mL and filtered (0.2 μm pore size). Formic acid and solvents (LC-MS grade water, methanol and acetonitrile) were purchased from Thermo Fisher Scientific (Bremen, Germany).

UPLC and MS conditions
The composition of phytochemicals in PJH was determined using a Dionex UltiMate 3000 system equipped with a Thermo Q-Exactive mass spectrometer. UPLC-DAD-MS/MS analyses were performed according to previously reported methods [29, 30]. Analyses were conducted using an electrospray ionization (ESI) source in both positive and negative ionization modes. MS spectra were acquired in full MS-ddMS² mode, and all data were acquired and processed using Xcalibur v.3.0 and TraceFinder v.3.2 software (Thermo Fisher Scientific).

Animals
Seven- week old male C57BL/6J mice were purchased from Orient Bio (Seongnam, South Korea). Animals
were acclimatized for 7 days prior to the start of dosing and were kept under environmentally constant conditions (22°C ± 2°C, 50% ± 5% humidity, 12-h light/dark cycle) throughout the experimental period. All animals were provided sterilized tap water and normal rodent chow ad libitum. Study procedures involving experimental animals were approved by the Animal Experimental Ethics Committee of Chungnam National University (Daejeon, South Korea).

CS/LPS-induced mouse model of COPD

Animals were randomly assigned into the following five groups (n = 7–8 per group): (1) normal control (NC group); (2) CS exposure combined with LPS intranasal administration (CS + LPS group); (3) CS/LPS administration plus roflumilast 5 mg/kg oral gavage (RO; positive control group); (4) CS/LPS administration plus PJH 100 mg/kg oral gavage (PJH 100 group); and (5) CS/LPS administration plus PJH oral gavage 200 mg/kg (PJH 200 group). 3R4F research cigarettes were obtained from the Tobacco and Health Research Institute at the University of Kentucky (Lexington, KY, USA). For CS exposure, mice housed in an exposure chamber were provided fresh room air or CS from eight cigarettes for 60 min/day. The CS lasted for 8 weeks with 5 days in a week. LPS was delivered as 100 μL (i.e., unstained) cells using at least five regions of tracheal cannula. BALF supernatant was transferred and used for further analysis. BALF was obtained by lavaging lungs three times by instilling and withdrawing 1.5 mL of phosphate-buffered saline (PBS) via a tracheal cannula. BALF (100 μL) were transferred on a slide, centrifuged and stained using Diff-Quik Stain reagents (B4132-1A; IMEB Inc., San Marcos, CA, USA).

Histopathological analysis

For histopathological examinations, tissue sections were prepared as previously described [31]. Briefly, lung tissues were fixed using 10% formalin, then embedded within paraffin, and then cut into 4-μm sections. Tissue sections were stained with H&E for histological analysis. For the analysis of collagen deposition in the lung, paraffin sections were stained with Sirius red, counterstained with Mayer’s hematoxylin, and analyzed via light microscopy.

Immunohistochemistry (IHC) assay

IHC was performed as previously described [31]. Briefly, primary antibody against matrix metalloproteinase (MMP)-7 (Abcam, Cambridge, UK) was applied over night in 200:1 diluted solution according to manufacturer’s guide. The positive area calculated in each lung tissues of at least 5 animals per group.

Enzyme-linked Immunosorbent assay (ELISA)

According to the manufacturer’s instructions, we performed ELISA for determination of the cytokines. The concentrations of IL-6 and TNF-α in BALF were detected using commercial ELISA kits (R&D System, MN, USA). Absorbance was measured at 450 nm using a microplate reader (Infinte m200pro; Tecan Life Sciences, Männedorf, Switzerland).

RNA extraction and qPCR analysis of mRNA expression

Total RNA was extracted using an RNeasy mini kit (Qiagen, MD, USA). The purity of isolated RNA was evaluated based on the A260/A280 ratio, and the concentration of total RNA was evaluated based on the absorbance at 260 nm. Quantitative RT-PCR was performed using an Applied Biosystems 7500 Real-Time PCR System (Life Technologies, CA, USA) and SYBR Green PCR Master Mix (Life Technologies) as described in the manufacturer’s manual. The following PCR primer pairs were used: TNF-α, 5′-GTC TGT GCC TCA GCC TCT TC-3′ (forward) and 5′-CTT TGG GAA CTT CCC T-3′ (reverse); IL-6, 5′-TAG TTC TCT CTA CCC CAA CT-3′ (forward) and 5′-TTG GTC ATT AGC TAC TCC TT-3′ (reverse); IL-1β, 5′-AGG ACC CAA GCA CCT TCT TT-3′ (forward) and 5′-AGAC AGC ACG AGG CAT TTT TT-3′ (reverse); TGF-β, 5′-TTG TTT CAG CTC CAC AGA GA-3′ (forward) and 5′-TTG GGG TTT AGA GGG CAA GGA C-3′ (reverse); MMP-7, 5′-GTT TTT GAT GCT ATT GCT GA-3′ (forward) and 5′-CCC ACC TTT GAC GTC CAG TCC AGA G-3′ (reverse); MMP-9, 5′-ACG ACA TAG AGC CCA TCC AGT-3′ (forward) and 5′-AGG...
TAT AGT GGG ACG ACT GGG-3’ (reverse); and GAPDH, 5’-ACA GCA ACA GGG TGG TGG AC-3’ (forward) and 5’-TTT GAG GGT GCA GCG AAC TT-3’ (reverse). Quantitative PCR results were analyzed using Applied Biosystems 7500 Real-Time PCR System software (Applied Biosystems, CA, USA) and are presented as fold-change in the cDNA level of the target gene relative to that of the endogenous constitutive control (GAPDH), determined using the 2-ΔΔCₜ method as described previously [32].

Western blot analysis

Equal amounts of total lung protein (35 μg) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF) membranes at 35 V for 2h. After blocking, membranes were incubated overnight at 4°C with anti-NF-κB, anti-phospho-NF-κB, anti-ERK1/2, anti-phospho-ERK1/2 (Cell Signaling Technology, MA, USA) or anti-β-actin (Sigma Aldrich, MO, USA) antibodies. The membranes were washed with phosphate-buffered saline containing 0.1% Tween-20 (PBS-T) and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody. After washing with PBS-T, membranes were developed using an enhanced chemiluminescence (ECL) kit (Thermo Scientific, MA, USA).

Statistical analysis

Data are expressed as means ± standard deviation (SD). Statistical comparisons were made by one-way analysis of variance (ANOVA) using SPSS 16.0 (IBM, USA), followed by Dunnett’s multiple comparisons test. A P-value <0.05 was considered statistically significant.

Results

UPLC-DAD-MS/MS analysis of PJH

To determine the phytochemicals in PJH, consisting of the eight herbal medicines, Dioscorea batatas, Paeonia suffruticosa, Rehmannia glutinosa, Cornus officinalis, Aconitum carmichaelii, Cinnamomum cassia, Alisma orientale and Poria cocos [33], we performed

Table 1: UPLC-DAD-MS/MS analysis of phytochemicals in PJH

| No. | RT (min) | Formula | Adduct | Calculated (m/z) | Measured (m/z) | Error (ppm) | MS/MS (m/z) | Identifications |
|-----|----------|---------|--------|----------------|----------------|-------------|-------------|----------------|
| 1   | 1.34     | C₆H₇NO₃ | M-H    | 157.0356       | 157.0352       | -2.9312     | -            | alantoin [34]  |
| 2   | 2.31     | C₇H₈NO₄ | M-H    | 169.0131       | 169.0128       | -1.8762     | 169.0127, 125.0277 | gallic acid [35] |
| 3   | 3.66     | C₈H₁₀N₂ | M-H    | 127.039        | 127.0388       | -1.3138     | 127.0388, 109.0286 | 5-hydroxymethyl-2-furaldehyde [36] |
| 4   | 4.81     | C₉H₁₂O₄ | M-H    | 375.1297       | 375.1290       | -1.7919     | 375.1288, 213.0756, 169.0854, 151.0745, 99.0432 | loganic acid [37] |
| 5   | 5.05     | C₁₀H₇O₉ | M-H    | 495.1497       | 495.1497       | 0.0952      | 495.1493, 465.1373, 333.0974, 165.0540, 137.0227 | oxypeaonflorin [35] |
| 6   | 5.07     | C₁₀H₇O₉ | M-H    | 139.039        | 139.0385       | -3.2855     | 139.0386, 121.0283 | 4-hydroxybenzoic acid [36] |
| 7   | 5.09     | C₁₁H₁₁O₅ | M+HCO₃ | 451.1457       | 451.1447       | -2.1593     | 243.0865, 179.0544, 155.0333, 141.0540, 123.0431 | morrin [37] |
| 8   | 5.47     | C₁₉H₂₈O₁₁ | M-H | 179.0338       | 179.0337       | -1.1677     | 179.0335, 135.0434 | caffeic acid [37] |
| 9   | 5.49     | C₁₉H₂₈O₁₁ | M+HCO₃ | 545.2799       | 545.2781       | -3.9464     | 545.2783 | fuzline [38] |
| 10  | 5.56     | C₁₉H₂₈O₁₁ | M+HCO₃ | 505.1552       | 505.1553       | 0.2417      | 293.0879, 239.0661, 165.0541 | paenolide [35] |
| 11  | 5.61     | C₁₉H₂₈O₁₁ | M+HCO₃ | 435.1508       | 435.1496       | -0.2423     | 227.0916, 127.0378, 101.0224 | larin [37] |
| 12  | 5.79     | C₁₉H₂₈O₁₁ | M+HCO₃ | 505.1563       | 505.1554       | 0.4229      | 293.0866, 165.0541 | apiopaeonflorin [35] |
| 13  | 5.79     | C₁₉H₂₈O₁₁ | M+HCO₃ | 403.1235       | 403.1236       | 0.3444      | 357.1180, 195.0650, 179.0541, 125.0226, 81.0527 | sweroside [37] |
| 14  | 5.89     | C₁₉H₂₈O₁₁ | M-H | 327.1074       | 327.1079       | 1.3319      | 327.1071, 165.0541 | paenoniflorin [35] |
| 15  | 6.00     | C₁₉H₂₈O₁₁ | M+H | 481.1704       | 481.1687       | -3.6772     | 179.0697, 151.0749, 133.0645 | albiflorin [35] |
| 16  | 6.26     | C₁₉H₂₈O₁₁ | M+HCO₃ | 525.1603       | 525.1600       | -0.4438     | 449.1456, 327.1077, 165.0542, 121.0277 | paenoniflorin [35] |
| 17  | 7.72     | C₁₉H₂₈O₁₁ | M-H | 541.1563       | 541.1552       | -1.9728     | 541.1540, 169.0127, 125.0226 | comuside [37] |
| 18  | 8.45     | C₁₉H₂₈O₁₁NO₃ | M+H | 590.2960       | 590.2938       | 0.7952      | 590.2941, 540.2575 | benzoylmesaconine [38] |
| 19  | 8.68     | C₂₀H₂₂O₂ | M-H | 147.0441       | 147.0436       | -3.1667     | 147.0436, 103.0544, 91.0545, 65.0393 | coumarin [39] |
| 20  | 10.73    | C₂₀H₂₂O₂ | M+HCO₃ | 629.1876       | 629.1862       | -0.4192     | 431.1345, 165.0542, 121.0277 | benzoylpaenonflorin [35] |
| 21  | 11.83    | C₂₀H₂₂O₂ | M-H | 167.0703       | 167.0698       | -0.5769     | 167.0698 | paeonol [35] |
| 22  | 17.74    | C₂₀H₂₂O₂ | M+HCO₃ | 535.3629       | 535.3629       | -0.1426     | 535.3597, 471.3463 | alisol A [40] |
| 23  | 20.56    | C₂₀H₂₂O₂ | M-H | 527.3731       | 527.3730       | -0.2186     | - | pachymic acid [41] |
ultra-high-performance liquid chromatography coupled with diode array detection and tandem mass spectrometry (UPLC-DAD-MS/MS) analysis. The compounds in PJH were separated on an Acquity BEH C18 column (100 × 2.1 mm, 1.7 μm; Waters) by gradient elution using a 21-min program employing 0.1% (v/v) formic acid in water and acetonitrile. MS spectra were acquired in both (+)-ESI and (−)-ESI modes. A total of 23 compounds were identified, including allantoin from *D. batatas* [34]; gallic acid, oxypaeoniflorin, paeonolide, apiopaeonoside, paeonoside, albiflorin, paeoniflorin, benzoylpaeoniflorin and paeonol from *P. suffruticosa* [35]; 5-hydroxymethyl-2-furaldehyde and 4-hydroxybenzoic acid from *R. glutinosa* [36]; loganic acid, morroniside, caffeic acid, loganin, sweroside and cornuside from *C. officinalis* [37]; fuziline and benzoylmesaconine from *A. carmichaelii* [38]; coumarin from *C. cassia* [39]; alisol A from *A. orientale* [40]; and pachymic acid from *P. cocos* [41] (Table 1). In addition, precursor ions and MS/MS fragments of identified compounds

![Fig. 1](image-url) UPLC-DAD-MS/MS chromatograms of PJH. **a** LC chromatogram (250 nm) and base peak chromatograms in (+)-ESI and (−)-ESI modes. **b** Extracted ion chromatograms of the identified phytochemicals in PJH. 1, allantoin; 2, gallic acid; 3, 5-hydroxymethyl-2-furaldehyde; 4, loganic acid; 5, oxypaeoniflorin; 6, 4-hydroxybenzoic acid; 7, morroniside; 8, caffeic acid; 9, fuziline; 10, paeonolide; 11, loganin; 12, apiopaeonoside; 13, sweroside; 14, paeonoside; 15, albiflorin; 16, paeoniflorin; 17, cornuside; 18, benzoylmesaconine; 19, coumarin; 20, benzoylpaeoniflorin; 21, paeonol; 22, alisol A; 23, pachymic acid

![Fig. 2](image-url) Effects of PJH on CS/LPS-induced histological changes in lung tissue. Lung tissues were fixed, sectioned at 4-μm thickness, stained with H&E, and examined under a microscope. **A** CON: control; **B** CS + LPS: CS/LPS-exposed; **C** RO: administration of roflumilast 10 mg/kg prior to CS/LPS exposure; **D** PJH 100: administration of PJH 100 mg/kg prior to CS/LPS exposure; **E** PJH 200: administration of PJH 200 mg/kg prior to CS/LPS exposure
Fig. 2 (See legend on previous page.)
were compared with results obtained in a previous study. Phenols, iridoids, terpenoids, and phenylpropa-
noi d were more suitably ionized in negative ion mode, whereas other types were detected clearly in positive ion mode. The LC chromatogram at 250 nm and base
peak chromatograms of PJH in positive and negative ion modes are shown in Fig. 1 together with the extracted
ion chromatograms for each compound.

Effects of PJH on CS/LPS-induced histological damage in mouse lung tissue
To examine pulmonary histopathological changes resulting from treatment with PJH, we performed
hematoxylin and eosin (H&E) staining. Sections of lung from the control group presented a normal bron-
choalveolar phenotype with few inflammatory infil-
trations (Fig. 2). Lung tissues from the CS/LPS group exhibited severe infiltration of inflammatory cells in
peribronchial and alveolar lesions (Fig. 2). Notably, infiltration of inflammatory cells was reduced in tis-
sues from mice treated with roflumilast or either dose of PJH compared with CS/LPS-treated mice (Fig. 2).

Effects of PJH on the number of inflammatory cells in BALF
We next evaluated effects of PJH on CS/LPS-induced pulmonary inflammation responses by performing cell
counts in BALF. The number of total cells, macrophages, and neutrophils in BALF were determined. Total
inflammatory cells and macrophages in BALF from the
CS/LPS-treated group were significantly higher compared with those in the control group (Fig. 3A and
B). In contrast, mice treated with roflumilast or either dose of PJH showed significantly decreased numbers
of total cells and macrophages in BALF compared with
CS/LPS-exposed animals (Fig. 3A and B). The number
of neutrophil in BALF was reduced in roflumilast- and
PJH-treated groups compared with CS/LPS-treated
group, but the decrease was not statistically significant
(Fig. 3C).

Effects of PJH on pro-inflammatory cytokine levels in BALF
To examine the effect of PJH on pro-inflammatory
cytokine production, we quantified TNF-α and IL-6 in
BALF using enzyme-linked immunosorbent assays (ELI-
SAs). Compared with the control group, CS/LPS-treated
mouse showed significantly elevated TNF-α and IL-6 levels
in BALF (Fig. 4). Treatment with roflumilast or PJH sup-
pressed the elevation of TNF-α and IL-6 in BALF com-
pared with that observed in CS/LPS-exposed mice
(Fig. 4).

Effects of PJH on relative mRNA levels of cytokines in lung tissues
We then evaluated mRNA expression of several cytokines in lung tissue using quantitative reverse-transcrip-tion-polymerase chain reaction (qPCR). CS/LPS-exposed mice showed a notable increase in the mRNA levels of TNF-α,
IL-6 and IL-1β compared with control mice (Fig. 5). Consis-
tent with their effects in BALF, roflumilast and PJH sig-
nificantly decreased IL-1β, IL-6 and TNF-α mRNA levels
in lung tissues compared with those in CS/LPS-exposed
mice (Fig. 5).

Effects of PJH on NF-κB and ERK1/2 pathways
Western blot analyses showed that phosphorylation of the p65 NF-κB subunit increased markedly in lung tis-
ssue from CS/LPS-treated mice. In contrast, tissues from
roflumilast- or PJH-treated animals showed no increase
in p65 NF-κB phosphorylation (Fig. 6A). Similarly, phos-
phorylated ERK1/2 was increased in CS/LPS-exposed
mice, an effect that was reversed in roflumilast- and PJH-
treated animals (Fig. 6B).

PJH effects on structural changes in the lung induced by CS/LPS treatment
Tissue remodeling in small airway walls and alveoli are key pathologies of COPD [42]. The major structural
changes in tissue in COPD lungs include increased interstitial extracellular matrix (ECM) deposition and peri-bronchiolar fibrosis. Sirius-red staining showed increased peribronchial collagen deposition in the
lungs of CS/LPS-exposed mice and this elevation were
significantly alleviated in mice treated with roflumi-
last or PJH (Fig. 7A). In addition, the positive area of
MMP-7 was increased in CS/LPS-treated animals com-
pared to control group, but this elevation was attenu-
ated in roflumilast or PJH-treated animals (Fig. 7A).
Consistently, treatment with CS/LPS increased mRNA expression of structural remodeling markers, including
MMP-7 and MMP-9. In addition, the relative expression of TGF-β, a marker of lung fibrosis, was increased by
CS/LPS treatment. Again, expression of these markers

(See figure on next page.)

**Fig. 3** Effects of PJH on CS/LPS-induced changes in inflammatory cell counts in BALF. A Number of total cells in BALF. B Number of macrophages in BALF. C Number of neutrophils in BALF. CON: control group; CS + LPS group: CS/LPS-exposed; RO group: administration of roflumilast 10 mg/
kg prior to CS/LPS exposure; PJH 100 group: administration of PJH 100 mg/kg prior to CS/LPS exposure; PJH 200 group: administration of PJH 200 mg/kg prior to CS/LPS exposure. Results are presented as means ± SD (*P < 0.05, **P < 0.01 compared with the CON group,*P < 0.05, **P < 0.01 compared with the CS + LPS group).
Fig. 3  (See legend on previous page.)
was repressed in roflumilast- and PJH-treated animals compared with animals in the CS/LPS-treatment group (Fig. 7B).

**Discussion**

COPD is a chronic and incompletely reversible inflammatory disease characterized by progressive airflow limitations, mucous overproduction, chronic bronchitis, and remodeling of small airways [1]. Chronic exposure to CS is a major factor in the development of COPD [5]. CS not only induces extensive airway inflammation but also promotes collagen deposition in lung tissue, resulting in pulmonary fibrosis [5]. In the present study, we evaluated the protective effects of PJH in a CS/LPS-induced mouse model of COPD. Treatment with PJH markedly decreased the infiltration of inflammatory cells and production of proinflammatory cytokines in BALF and lung tissue induced by CS/LPS exposure. PJH also significantly suppressed CS/LPS-induced increases in MMP-7, MMP-9, and TGF-β levels and collagen deposition.

Inflammation is a key contributing factor to lung disease and airflow limitations in COPD [43]. Especially, CS encompass innate immune, which release pro-inflammatory cytokines and chemokines, such as TNF-α, IL-6, IL-1β and IL-8 by airway epithelial cells and alveolar macrophages. These cytokines elicit the expression of adhesion molecules on endothelial cells and the recruitment of inflammatory macrophages to the lungs [43, 44]. TNF-α, can induce the production of CXCL10, a potent chemoattractant for leukocytes such as monocytes, neutrophils and Th1 cells, and thus induces pulmonary emphysema [45, 46]. Macrophages produce IL-6, which has neutrophil chemotactic effects and is related to the severity of disease [45, 47]. IL-1β causes disruption of elastin layer fibers in alveolar septa, fibrosis in airway walls, enhanced mucin production, and formation of lymphocyte aggregates in airways [48]. In the present study, PJH treatment significantly attenuated inflammatory cell infiltration into lung tissue and reduced inflammatory cell counts (total cells and macrophages) in BALF. Furthermore, PJH reduced the production of proinflammatory cytokines, including TNF-α, IL-6 and IL-1β, in BALF and lung induced by CS/LPS exposure. These effects of PJH are consistent with those observed in a previous study by Jin et al., who showed that PJH inhibits the production of inflammatory mediators and cytokines in LPS-treated RAW 264.7 cells [49]. These observations, taken together with our findings, suggest that PJH suppresses the inflammatory response associated with COPD.

TNF-α, IL-6 and IL-1β appear to amplify inflammation in COPD, in part through the activation of the transcription factor, NF-κB and MAPK, thereby leading to the increased expression of multiple inflammatory genes [50]. Previous studies have demonstrated that NF-κB and MAPK are activated in bronchial biopsies and inflammatory cells of COPD individuals [51]. In addition, CS induces inflammatory cell infiltration through
Fig. 5 (See legend on previous page.)
enhancement of NF-κB and MAPK phosphorylation [51]. Therefore, we further tested whether NF-κB and MAPK played regulatory roles in the protective effects of PJH. Consistent with these previous results, we found that CS/LPS exposure caused activation of NF-κB and ERK1/2 in lung tissue. Notably, PJH treatment evoked a significant decrease in phosphorylation of NF-κB and ERK1/2 in this mouse model of COPD, indicating that the protective effects of PJH on airway inflammatory responses induced by CS/LPS are likely closely associated with downregulation of NF-κB and ERK1/2 phosphorylation.

Small airways in COPD patients exhibit marked histological remodeling, with increased thickness of the airway wall compared with those of smokers, an increase attributable to changes in epithelial cells, increases in inflammatory cells, hyperplasia of smooth muscle tissue, and fibrosis [52]. Airway remodeling is mediated by a wound healing mechanism triggered by damage induced by CS and/or bacterial infection. The wound healing mechanism is controlled by interactions between the immune response and remodeling of extracellular matrix (ECM) by myofibroblasts in response to these stimuli [53]. The major structural changes in COPD lungs include increased interstitial ECM deposition and peri-bronchiolar fibrosis. Published experimental results suggest that the levels of several MMPs are increased in chronically inflamed lung tissues in disease states such as COPD [54]. Macrophages express numerous MMPs, and alveolar macrophages from COPD patients release large amounts of MMP-1 and MMP-9 with increased enzymatic activity compared with those of non-smokers or healthy smokers [55]. Notably, a previous report demonstrated that inhibition of MMP-9/MMP-12 considerably suppresses emphysema morphology and small airway remodeling [56]. In this study, PJH administration attenuated collagen accumulation in bronchioles and suppressed the elevated levels of

**Fig. 6** Effects of PJH on CS/LPS-induced changes in NF-κB and ERK1/2 activation. Western blot analysis was performed in lung tissues to examine the phosphorylation of NF-κB and ERK1/2. CON: control group; CS+LPS group: CS/LPS-exposed; RO group: administration of roflumilast 10 mg/kg prior to CS/LPS exposure; PJH100 group: administration of PJH 100 mg/kg prior to CS/LPS exposure; PJH200 group: administration of PJH 200 mg/kg prior to CS/LPS exposure. Results are presented as means ± SD (*P < 0.05, **P < 0.01 compared with the CON group; *P < 0.05, **P < 0.01 compared with the CS+LPS group). Gels/blots are cropped for a clear presentation of results. Full-length blots/gels are presented in Supplementary Fig. 1. Protein samples derived from the same experiment and gels/blots were processed in parallel.
TGF-β in mice exposed to CS/LPS. These results show that the protective effect of PJH on COPD might be associated with its protective effects on pulmonary remodeling and fibrosis.

Conclusions
The present results demonstrate that PJH treatment significantly reduces the inflammatory response and airway remodeling induced by CS/LPS exposure, and decreases phosphorylation of NF-κB and ERK1/2. Our study provides evidence that PJH exhibits therapeutic potential to prevent COPD.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12906-021-03453-5.

Addendum 1: Supplementary Fig. 1.1 The Uncropped Blot of p-NF-κB (65 kDa). The red arrow indicates the location of target bands. Blue box indicates the cropped region of Fig. 6A. Supplementary Fig. 1.2 The Uncropped Blot of p-NF-κB (65 kDa). The red arrow indicates the
location of target bands. Supplementary Fig. 1.3 The Uncropped Blot of NF-xB (65 kDa). The red arrow indicates the location of target bands. Supplementary Fig. 1.5 The Uncropped Blot of α-actin (42 kDa). The red arrow indicates the location of target bands. Blue box indicates the cropped region of Fig. 6A. Supplementary Fig. 1.4 The Uncropped Blot of NF-xB (65 kDa). The red arrow indicates the location of target bands. Supplementary Fig. 1.6 The Uncropped Blot of β-actin (42 kDa). The red arrow indicates the location of target bands. Supplementary Fig. 1.7 The Uncropped Blot of p-ERK1/2 (44/42 kDa). The red arrow indicates the location of target bands. Blue box indicates the cropped region of Fig. 6B. Supplementary Fig. 1.8 The Uncropped Blot of p-ERK1/2 (44/42 kDa). The red arrow indicates the location of target bands. Supplementary Fig. 1.9 The Uncropped Blot of ERK1/2 (44/42 kDa). The red arrow indicates the location of target bands. Supplementary Fig. 1.10 The Uncropped Blot of ERK1/2 (44/42 kDa). The red arrow indicates the location of target bands. Supplementary Fig. 1.11 The Uncropped Blot of β-actin (42 kDa). The red arrow indicates the location of target bands. Blue box indicates the cropped region of Fig. 6B. Supplementary Fig. 1.12 The Uncropped Blot of β-actin (42 kDa). The red arrow indicates the location of target bands.

Acknowledgments
Not applicable.

Authors’ contributions
Conceptualization and design of the work: H.J. Kwun; data acquisition, analysis and interpretation: E.B. Baek, J.H. Rho, E. Jung, C.S. Seo and J. H Kim; writing–original draft preparation: E.B. Baek; writing–review and editing: E.B. Baek; supervision: H.J. Kwun; All authors have read and agreed to the published version of the manuscript.

Funding
This research was supported by a grant from the Korea Institute of Oriental Medicine (grant number KSN2013220 and KSN2021220).

Availability of data and materials
All the data generated and analyzed in this study are mentioned in this manuscript.

Declarations

Ethics approval and consent to participate
Study procedures involving experimental animals were approved by the Animal Experimental Ethics Committee of Chungnam National University (Daejeon, South Korea). The present study procedures were performed in accordance with ARRIVE guidelines and the principles of the Institutional Animal Care and Use Committee (IACUC) of Chungnam National University.

Consent for publication
All authors of the manuscript have read and agreed to its content.

Competing interests
The authors declare that this article involves no conflict of interest.

Author details
1 Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, 220 Gong-dong, Yuseong-gu, Daejeon 34134, South Korea.
2 Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, South Korea.

Received: 21 July 2021 Accepted: 19 October 2021 Published online: 16 November 2021

References
1. Barnes PJ, Burney PG, Silverman EK, Cells BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076).
2. Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respirat. 2012;84(2):89–97.
3. Riley CM, Sciruba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321(8):786–97.
4. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015–26.
5. Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J Thorac Dis. 2019;11(Suppl 17):S2129–S40.
6. McGuinness AJ, Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J Clin Med. 2017;6(2):21–38.
7. Rosenberg SR, Kallhan R. Recent advances in the management of chronic obstructive pulmonary disease. F1000Res. 2017;6:863.
8. Fernandes FLA, Cukier A, Camelier AA, Fritscher CC, Costa CHD, Pereira EDB, et al. Recommendations for the pharmacological treatment of COPD: questions and answers. J Bras Pneumol. 2017;43(4):290–301.
9. Guo R, Pritter MH, Ernst E. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J. 2006;28(2):330–8.
10. van Eeden SF, Sin DD. Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process. Can Respir J. 2013;20(1):127–9.
11. Sung W-S, Jeon S-R, Hong Y-J, Kim T-H, Shin S, Lee H-J. Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blind, multicenter clinical trial. J Med Food. 2019;21(1):778.
12. Lee WC, Wu CC, Chung YC, Tian YL, Chiang PH. Ba-Wei-die-Huang-wan (Hachimi-jio-Gan) can ameliorate cyclophosphamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder. J Ethnopharmacol. 2016;184:1–9.
13. Isobe H, Yamamoto K, Cyong JC. Effects of hachimi-jio-Gan (Ba-wei-die-Huang-wan) on blood flow in the human central retinal artery. Am J Chin Med. 2003;31(3):425–35.
14. Iwasaki K, Kobayashi S, Chimura Y, Taguchi M, Inoue K, Cho S, et al. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine “Ba wei di huang wan” in the treatment of dementia. J Am Geriatr Soc. 2004;52(9):1518–21.
15. Kawago K, Shindo S, Inoue H, Akasaka J, Motohashi S, Urabe G, et al. The effect of Hachimi-jio-Gan (Ba-Wei-Di-Huang-wan) on the quality of life in patients with peripheral arterial disease – a prospective study using Kampo medicine. Ann Vasc Dis. 2016;9(4):289–94.
16. Byeon S, Oh J, Lim JS, Lee JS, Kim JS. Protective effects of Dioscorea batatas flesh and Peel extracts against ethanol-induced gastric ulcer in mice. Nutrients. 2018;10(11):1680–93.
17. Ji Sun Lim DH, Gu MJ, Oh J, Lee JS, Kim JS. Anti-inflammatory and anti-oxidant effects of 2, 7-dihydroxy-4, 6-dimethoxy phenanthrene isolated from Dioscorea batatas Decne. Appl Biol Chem. 2019;62:29.
18. Kim HP, Lim H, Kwon YS. Therapeutic potential of medicinal plants and their constituents on lung inflammatory disorders. Biomol Ther (Seoul). 2017;25(2):91–104.
19. Lee H, Kim Y, Kim H, Park S, Jang YP, Jung S, et al. Herbal formula, PM014, attenuates lung inflammation in a murine model of chronic obstructive pulmonary disease. Evid Based Complement Alternat Med. 2012;2012:769830.
20. Kim SH, Kim BK, Lee YC. Effects of Corin fructus on ovalbumin-induced airway inflammation and airway hyper-responsiveness in a mouse model of allergic asthma. J Inflamm (Lond). 2012;9(1):9.
21. Huang J, Zhang Y, Dong L, Gao Q, Yin L, Quan H, et al. Ethnopharmacology, phytochemistry, and pharmacology of Corrus officinalis Sieb. et Zucc. J Ethnopharmacol. 2018;213:280–301.
22. You Q, Wang J, Jiang L, Chang Y, Li W. Aqueous extract of Aconitum carmichaeli Debeaux attenuates sepsis-induced acute lung injury via regulation of TLR4/NF-κB pathway. Trop J Pharm Res. 2020;19(3):533–9.
23. Park G, Lee SH, Han JY, Oh DS. Altered TNF-alpha response by Aconitum(R) and methotrexate in a lipopolysaccharide-induced setting of inflammatory conditions: potential on a synergistic combination. J Ethnopharmacol. 2018;213:191–7.

24. Liou SS, Liu IM, Lai MC, Cheng JT. Comparison of the antinociceptive action of crude Fuzei, the root of aconitum, and its processed products. J Ethnopharmacol. 2005;99(3):379–83.

25. Yeh CF, Chang JS, Wang KC, Shieh DE, Chiang LC. Water extract of Cinmanomum cassia Blume inhibited human respiratory syncytial virus by preventing viral attachment, internalization, and syncytium formation. J Ethnopharmacol. 2013;147(2):321–6.

26. Liao JC, Deng JS, Chiu CS, Hou WC, Huang SS, Shiie PH, et al. Anti-inflammation activities of Cinmanomum cassia constituents in vitro and in vivo. Evid Based Complement Alternat Med. 2012;2012:429320.

27. Kim KH, Song HH, Ahn KS, Oh SR, Sadikot RT, Joo M. Ethanol extract of Poria cocos blocked TGF-β and TNF-α expression in vivo and in vitro: potential anti-inflammatory and anti-angiogenic activity. J Ethnopharmacol. 2017;199:232–40.

28. Cheng P, Chen Y, Zhang J, Ye XQ, Cai D, et al. Cytoxic constituents from the Sclerotia of Poria cocos against human lung adenocarcinoma cells by inducing mitochondrial apoptosis. Cells. 2018;7(9):116–28.

29. Jaroouche M, Suresh L, Low M, Lee S, Xu K, Choo KQ. Quality control and variability assessment of an eight-herb formulation for hyper tension using method validation and statistical analysis. Molecules. 2019;24(8):1550–34.

30. Kwang HY, Ma JY. Preventive effects of an UPLC-DAD-MS/MS finger printed Hydroalcoholic extract of Citrus aurantium in a mouse model of ulcerative colitis. Planta Med. 2018;84(15):1101–9.

31. Rho J, Seo CS, Park HS, Jeong HY, Moon OS, Seo YW, et al. Asteris radix et rhizoma suppresses testosterone-induced benign prostatic hyperplasia in rats by regulating apoptosis and inflammation. J Ethnopharmacol. 2020;255:112779.

32. Park HS, Wijerathne CUB, Jeong HY, Seo CS, Ha H, Kwon HJ. Gastroprotective effects of Hwangyeonhaedok-tang against helicobacter pylori-induced gastric cell injury. J Ethnopharmacol. 2018;216:239–50.

33. Jung-Hoon Kim H-K, Chang-Seob Seo. Development of a quantitative analysis method for the 12 marker compounds in Palmijihwang-hwan, a herbal formula, using a reversed-phase C18 column and an amino column by HPLC. Anal Methods. 2014;6:3763–71.

34. Yu YG, Guo XY, Li XY, Dai DD, Xu KR, Ge XJ, et al. Organ- and age-specific differences of Dioscorea polystachya compounds measured by UPLC-QTOF/MS. Chem Biodivers. 2021;18(2):e2000856.

35. Xu SJ, Yang L, Zeng X, Zhang M, Wang ZT. Characterization of compounds in the Chinese herbal drug Mu-Dan-pi by liquid chromatography coupled to electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(22):3275–88.

36. Duan X, Pan L, Bao Q, Peng D. UPLC-Q-TOF-MS study of the mechanism of THSWD for breast cancer treatment. Front Pharm. 2019;10:1625.

37. Xue C, Zhang A, Sun H, Han Y, Zou D, Wang Y, et al. An improved method for the simultaneous determination of eight triterpene compounds from Poria cocos (Schwein) wolf in extract in rat plasma application to a comparative pharmacokinetic study. J Chromatogr B Anal Technol Biomed Sci. 2018;1102–1103:34–44.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.